Polaris Pharmaceuticals-KY (6550) Announces Key Resolutions from 2026 Annual General Meeting
Polaris Pharmaceuticals-KY (6550) announced on May 15, 2026, the important resolutions passed at its 2026 Annual General Meeting. The meeting approved the compensation for the 2025 fiscal year's losses and the 2025 business report and financial statements. A significant decision was the election of new directors, including independent directors. Additionally, shareholders approved lifting non-compete restrictions for the newly elected directors, a capital reduction to offset losses, amendments to asset disposal procedures, and revisions to the Rules of Procedure for Shareholder Meetings. No amendments were made to the company's articles of incorporation.
📋 Article Processing Timeline
- 📰 Published: May 16, 2026 at 12:57
- 🔍 Collected: May 16, 2026 at 12:57 (0 min after Published)
- 🤖 AI Analyzed: May 16, 2026 at 14:46 (1h 48m after Collected)
Announcement Date: May 16, 2026
Date of Announcement: May 15, 2026
Time of Announcement: 21:15:06
Company Code: 6550
Company Name: Polaris Pharmaceuticals-KY
Subject: Announcement of Important Resolutions from the Company's 2026 Annual General Meeting
Compliance Clause: Clause 18
Date of Event: May 15, 2026
Description:
1. Date of Shareholder Meeting: May 15, 2026
2. Important Resolution I: Profit Distribution or Loss Compensation: Approval of the 2025 loss compensation proposal.
3. Important Resolution II: Amendment of Articles of Incorporation: None.
4. Important Resolution III: Business Report and Financial Statements: Approval of the 2025 business report and financial statements proposal.
5. Important Resolution IV: Election of Directors and Supervisors: Full re-election of the company's directors (independent directors).
6. Important Resolution V: Other Matters:
(1) Proposal to lift non-compete restrictions for new directors and their representatives.
(2) Approval of the company's proposed capital reduction to offset losses.
(3) Amendment to the asset disposal procedures.
(4) Amendment to the Rules of Procedure for Shareholder Meetings.
7. Other Matters to be Noted: None.
Date of Announcement: May 15, 2026
Time of Announcement: 21:15:06
Company Code: 6550
Company Name: Polaris Pharmaceuticals-KY
Subject: Announcement of Important Resolutions from the Company's 2026 Annual General Meeting
Compliance Clause: Clause 18
Date of Event: May 15, 2026
Description:
1. Date of Shareholder Meeting: May 15, 2026
2. Important Resolution I: Profit Distribution or Loss Compensation: Approval of the 2025 loss compensation proposal.
3. Important Resolution II: Amendment of Articles of Incorporation: None.
4. Important Resolution III: Business Report and Financial Statements: Approval of the 2025 business report and financial statements proposal.
5. Important Resolution IV: Election of Directors and Supervisors: Full re-election of the company's directors (independent directors).
6. Important Resolution V: Other Matters:
(1) Proposal to lift non-compete restrictions for new directors and their representatives.
(2) Approval of the company's proposed capital reduction to offset losses.
(3) Amendment to the asset disposal procedures.
(4) Amendment to the Rules of Procedure for Shareholder Meetings.
7. Other Matters to be Noted: None.
FAQ
When was the Annual General Meeting held?
The Annual General Meeting was held on May 15, 2026.
What were the main resolutions passed at the meeting?
The main resolutions included approving the compensation for the 2025 loss, approving the 2025 business report and financial statements, electing new directors, lifting non-compete restrictions for new directors, approving a capital reduction to offset losses, amending asset disposal procedures, and amending the Rules of Procedure for Shareholder Meetings.
Was there any change to the company's articles of incorporation?
No, there were no amendments to the company's articles of incorporation.
What is the company's stock code?
The company's stock code is 6550.